The present invention relates to agents that modulate/regulate the activity of the protein TMEM230 for use in the therapeutic treatment of pathologies in which therapeutic regulation of angiogenesis is advisable or necessary.

The present invention is directed to methods for detecting a plasma cell dyscrasia like myeloma or MGUS, methods for determining whether a plasma cell dyscrasiais stable or progressive, methods for determining a risk for disease relapse, and methods for determining a response by a subject having a plasma cell dyscrasia to a therapy.

This disclosure relates to the field of mass spectrometry analysis. In some embodiments, the disclosure relates to compositions and methods for detecting and quantifying proteins in the AKT-mTOR pathway by immunoprecipitation enrichment followed by mass spectrometry analysis.

Disclosed is a method of isolating extracellular vesicles and identifying membrane proteins therefrom. The method includes providing human plasma and/or serum; separating lipoproteins and extracellular vesicles from the human plasma and/or serum by a density gradient preparation, collecting the extracellular vesicles from the separated lipoproteins and extracellular vesicles; isolating and purifying the collected extracellular vesicles by using size exclusion chromatography; treating the isolated and purified extracellular vesicles with an aqueous solution to obtain membranes of the extracellular vesicles, wherein the aqueous solution has a pH in a range of 9 to 14; adding salt in a concentration range between 0.5-2.0M to the aqueous solution; isolating the membranes from the treated extracellular vesicles and identifying proteins on the isolated membranes by employing mass spectrometry.

The invention provides compositions, formulations, and methods for treatment of malignancies via activation of an inflammatory response in the subject. Such compositions, formulations, and methods for are preferably used in conjunction with other therapies for the treatment and/or management of malignancies, e.g., chemotherapy and/or radiation. The invention also provides methods of monitoring immune activation in subjects with malignancies.

Method and kits for detecting cancer, and in particular breast cancer, in a subject by measuring the levels of at least one of a series of biomarkers, as compared to a control sample lacking cancer. The expression of the biomarker either increases or decreases in samples from subjects with cancer, as compared to the expression level in subjects without cancer. The sample is optimally an ocular sample, such as an isolated tear sample or ocular wash, but can also be from saliva, or other bodily fluid. Kits can include a collection tube and protease inhibitors or protein stabilizers.

The methods of the present invention provide a new diagnostic marker for proliferative conditions and cancers, such as ovarian cancer, endometrial cancer and others. A truncation of MAP1a, CSP80 is an oncoprotein identified as being present in bodily fluids, or contents thereof, of a subject when afflicted with a proliferative condition. The present invention disclosed diagnosis and monitoring of a proliferative condition by detection of CSP80. Additionally, the present invention discloses a targeted treatment of proliferative conditions utilizing CSP80 binding agents, via a variety of delivery vehicles such as nanoparticles.

Described herein are methods such as multi-omic methods for assessing a disease such as cancer. The multi-omic methods may integrate proteomic, transcriptomic, genomic, lipidomic, or metabolomic data. The method screening diseases or disease states. Also described herein are methods for screening for diseases or disease states from biological samples. The methods may include assessing whether a nodule, mass, or cyst is cancerous.

Methods of determining suitability of a subject suffering from cancer or at risk of cancer relapse to receive treatment comprising an agent that reduces sCD28 levels are provided. Methods of treating a subject suffering from cancer or at risk of cancer relapse comprising administering an anti-PD-1/PD-L1 immunotherapy, measuring soluble CD28 levels in a subject, and administering an agent that reduces sCD28 levels to a subject whose sCD28 levels increased are also provided.

Disclosed herein are methods of detecting the presence or absence of exosomes, the method comprising detecting an exosomal biomarker in a sample obtained from a subject. Also disclosed herein is a system and a biosensor, each for detecting an exosomal biomarker as disclosed herein.